A double-blind, placebo-controlled, randomized, multicenter study to investigate the safety and efficacy of 2 mg TID of cilansetron over 12 weeks followed by a 4-week rerandomization treatment period in diarrhea predominate irritable bowel syndrome subjects

Trial Profile

A double-blind, placebo-controlled, randomized, multicenter study to investigate the safety and efficacy of 2 mg TID of cilansetron over 12 weeks followed by a 4-week rerandomization treatment period in diarrhea predominate irritable bowel syndrome subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2006

At a glance

  • Drugs Cilansetron (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Solvay Pharmaceuticals
  • Most Recent Events

    • 13 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top